Earnings Feed
Sign Up
Home/Filings/4/0001179110-09-012862
4//SEC Filing

Dietl Deanna 4

Accession 0001179110-09-012862

CIK 0000874255other
View on SEC.govCompany Profile

Filed

Sep 2, 8:00 PM ET

Accepted

Sep 3, 4:03 PM ET

Size

33.5 KB

Accession

0001179110-09-012862

Insider Transaction Report

Form 4
Period: 2009-09-01
MEDAREX INCMEDX
Dietl Deanna
VP, Human Resources
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−15,000$240,000→ 0 total
    Exercise: $10.06Exp: 2015-09-05→ Common Stock (15,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−17,174$274,784→ 0 total
    Exercise: $9.56Exp: 2016-07-27→ Common Stock (17,174 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−5,000$80,000→ 0 total
    Exercise: $3.43Exp: 2009-10-31→ Common Stock (5,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−3,959$63,344→ 0 total
    Exercise: $7.04Exp: 2012-07-10→ Common Stock (3,959 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−4,062$64,992→ 0 total
    Exercise: $6.46Exp: 2013-11-23→ Common Stock (4,062 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−2,826$45,216→ 0 total
    Exercise: $9.56Exp: 2016-07-27→ Common Stock (2,826 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−9,200$147,200→ 0 total
    Exercise: $6.33Exp: 2013-09-07→ Common Stock (9,200 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−13,000$208,000→ 0 total
    Exercise: $5.61Exp: 2014-07-25→ Common Stock (13,000 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−23,300$372,800→ 0 total
    Exercise: $3.72Exp: 2019-03-04→ Common Stock (23,300 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−15,536$248,576→ 0 total
    Exercise: $9.07Exp: 2018-03-02→ Common Stock (15,536 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−10,938$175,008→ 0 total
    Exercise: $6.70Exp: 2013-11-23→ Common Stock (10,938 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−6,041$96,656→ 0 total
    Exercise: $6.37Exp: 2012-07-10→ Common Stock (6,041 underlying)
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2009-09-01$16.00/sh−10,000$160,000→ 0 total
    Exercise: $5.19Exp: 2019-03-30→ Common Stock (10,000 underlying)
Footnotes (13)
  • [F1]This option was canceled in the merger in exchange for a cash payment of $89,100.00, repesenting the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement betweenthe issuer and Bristol-Myers Squibb.
  • [F10]This option was canceled in the merger in exchange for a cash payment of $135,135.00, repesenting the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement betweenthe issuer and Bristol-Myers Squibb.
  • [F11]This option was canceled in the merger in exchange for a cash payment of $108,150.00, repesenting the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement betweenthe issuer and Bristol-Myers Squibb.
  • [F12]This option was canceled in the merger in exchange for a cash payment of $286,124.00, repesenting the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement betweenthe issuer and Bristol-Myers Squibb.
  • [F13]This option was canceled in the merger in exchange for a cash payment of $62,850.00, repesenting the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement betweenthe issuer and Bristol-Myers Squibb.
  • [F2]This option was canceled in the merger in exchange for a cash payment of $18,213.57, repesenting the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement betweenthe issuer and Bristol-Myers Squibb.
  • [F3]This option was canceled in the merger in exchange for a cash payment of $110,686.43, repesenting the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement betweenthe issuer and Bristol-Myers Squibb.
  • [F4]This option was canceled in the merger in exchange for a cash payment of $107,742.16, repesenting the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement betweenthe issuer and Bristol-Myers Squibb.
  • [F5]This option was canceled in the merger in exchange for a cash payment of $35,472.64, repesenting the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement betweenthe issuer and Bristol-Myers Squibb.
  • [F6]This option was canceled in the merger in exchange for a cash payment of $101,723.40, repesenting the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement betweenthe issuer and Bristol-Myers Squibb.
  • [F7]This option was canceled in the merger in exchange for a cash payment of $38,771.79, repesenting the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement betweenthe issuer and Bristol-Myers Squibb.
  • [F8]This option was canceled in the merger in exchange for a cash payment of $58,174.83, repesenting the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement betweenthe issuer and Bristol-Myers Squibb.
  • [F9]This option was canceled in the merger in exchange for a cash payment of $88,964.00, repesenting the difference between the exercise price of the option and the merger consideration ($16 per share) pursuant to the Merger Agreement betweenthe issuer and Bristol-Myers Squibb.

Documents

1 file

Issuer

MEDAREX INC

CIK 0000874255

→
Entity typeother

Related Parties

1
  • filerCIK 0001460343

Filing Metadata

Form type
4
Filed
Sep 2, 8:00 PM ET
Accepted
Sep 3, 4:03 PM ET
Size
33.5 KB
View on SEC.gov